10x Genomics CFO sells 17K shares for taxes

10x Genomics, Inc. (TXG) reported that its Chief Financial Officer, Adam Taich, sold 17,166 shares of Class A common stock on 2026-08-24.

Rhea-AI Filing Summary

10x Genomics, Inc. (TXG) reported that its Chief Financial Officer, Adam Taich, sold 17,166 shares of Class A common stock on 2026-08-24. The filing states the shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units. The weighted average sale price was $63.023 per share, with individual trades executed between $63.0088 and $63.73. After these sales, Taich directly held 362,732 shares of Class A common stock.

Insider Trade Summary

Net Seller: 17,166 shares

Net Sell 1 txn

Insider Taich Adam

Role Chief Financial Officer

Sold 17,166 shs ($1.08M)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock F1, F2	17,166	$63.023	$1.08M

Holdings After Transaction: Class A Common Stock — 362,732 shares (Direct)

Footnotes (2)

1. F1. The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
2. F2. This transaction was executed in multiple trades at prices ranging from $63.0088 to $63.73, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Key Figures

Shares sold: 17,166 shares of Class A Common Stock Weighted average sale price: $63.023 per share Trade price range: $63.0088 to $63.73 per share +1 more

4 metrics

Shares sold 17,166 shares of Class A Common Stock Non-derivative sale on 2026-08-24

Weighted average sale price $63.023 per share Sale of 17,166 shares on 2026-08-24

Trade price range $63.0088 to $63.73 per share Multiple trades comprising the reported sale

Shares held after transaction 362,732 shares of Class A Common Stock Direct holdings by CFO Adam Taich following the sale

Key Terms

restricted stock units, tax withholding obligations, weighted average sale price

3 terms

restricted stock units financial

"in connection with the vesting of restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"sold to cover tax withholding obligations in connection"

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TXG CFO Adam Taich report on this Form 4?

Adam Taich, CFO of 10x Genomics (TXG), reported selling 17,166 shares of Class A common stock on 2026-08-24. The filing states these shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.

At what price were the TXG shares sold by CFO Adam Taich?

The reported weighted average sale price was $63.023 per share. A footnote explains the transaction was executed in multiple trades at prices ranging from $63.0088 to $63.73 per share, inclusive.

How many TXG shares does CFO Adam Taich hold after this transaction?

Following the reported sale, Adam Taich directly holds 362,732 shares of 10x Genomics Class A common stock, according to the Form 4 disclosure.

Why did TXG CFO Adam Taich sell shares according to the Form 4 footnote?

A footnote states the shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units, indicating the sale was related to equity award taxation.

Was the TXG Form 4 sale by CFO Adam Taich under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirmative for a trading plan, and the footnotes do not state that the sale was made pursuant to a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/26/2026 - 04:45 PM EDT Accepted by SEC EDGAR 08/26/2026 - 04:44 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Taich Adam

(Last) (First) (Middle)

10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON CALIFORNIA 94588

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	08/24/2026		S(1)		17,166	D	$63.023(2)	362,732	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

2. This transaction was executed in multiple trades at prices ranging from $63.0088 to $63.73, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

	/s/ Randy Wu, as Attorney-in-Fact for Adam Taich	08/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)